Can I Take Alpha-Lipoic Acid with BPC-157?

BPC-157 (body protection compound-157, a synthetic 15-amino-acid pentadecapeptide, not FDA-approved and available only through 503A compounding pharmacies for off-label or research use) and alpha-lipoic acid (ALA, also called thioctic acid, an FDA-recognized dietary supplement and, in some countries, an intravenous prescription product for diabetic neuropathy) are not known to interact at the level of absorption or metabolism. Both compounds independently influence blood glucose, and alpha-lipoic acid has a separate, dose-dependent signal on thyroid hormone levels. That combination of overlapping effects, not a drug-transporter or enzyme conflict, is the real interaction question here.

What kind of interaction is this?

The interaction, to the extent one exists, is pharmacodynamic rather than pharmacokinetic. There is no evidence that BPC-157 and alpha-lipoic acid compete for the same transporters, cytochrome enzymes, or absorption pathway. What they may share is a downstream effect on blood glucose and, for alpha-lipoic acid specifically, thyroid hormone economy.

This distinction matters practically. A pharmacokinetic interaction would call for strict timing separation. A pharmacodynamic overlap calls for watching shared endpoints, principally glucose and, in people on thyroid medication, TSH and free T4.

The glucose question

Alpha-lipoic acid's glucose-lowering activity is better established than BPC-157's. ALA is an endogenous mitochondrial cofactor with antioxidant properties, and oral and intravenous formulations have been studied in diabetic neuropathy trials, generally at doses in the 300 to 600 mg/day (oral) or higher (IV) range. Some trial and meta-analytic evidence has reported modest reductions in fasting glucose and HbA1c with ALA supplementation, though the exact magnitude reported in earlier drafts of this page could not be traced to a verifiable primary source and should not be treated as a precise figure until confirmed.

BPC-157's effect on glucose is far less established in humans. Rodent studies have reported improved glucose handling and reduced markers of diabetic tissue injury with BPC-157 administration, with proposed mechanisms involving nitric oxide signaling and growth-factor pathways. No completed human trial data on BPC-157 and glucose metabolism exist as of this writing. Because BPC-157 has not undergone controlled human study, any glucose-lowering effect in people is plausible by extrapolation from animal data, not established.

If both agents do lower glucose independently, even by a modest amount, the combined effect could matter more in someone already taking insulin, a sulfonylurea, or a GLP-1 receptor agonist such as semaglutide, where an added downward push on glucose is more likely to become symptomatic.

Does ALA blunt BPC-157's tissue-repair activity?

We found no evidence supporting the idea that alpha-lipoic acid's antioxidant activity interferes with BPC-157's proposed tissue-repair mechanisms. BPC-157's repair signaling in animal models is generally described through vascular endothelial growth factor and epidermal growth factor receptor pathways rather than reactive-oxygen-species-dependent signaling, so an antioxidant would not be expected to blunt it on mechanistic grounds. This is a plausibility argument based on proposed mechanism, not a demonstrated absence of interaction in a controlled study of the combination, because no such study of the combination exists.

What is the thyroid signal, and how solid is it?

This is the interaction question that deserves the most caution, and also the one where source verification is weakest in the material we reviewed.

Alpha-lipoic acid has been reported, in smaller case-level publications, to reduce circulating T4 or raise TSH in some patients on stable levothyroxine doses, with a proposed mechanism involving interference with peripheral T4-to-T3 conversion. A directly quoted case series describing this effect was present in an earlier draft of this page; we could not verify the exact citation, patient count, or wording of that quotation against a located primary source, so it has been removed rather than repeated. The underlying concern, that ALA may alter thyroid hormone measurements in some people on replacement therapy, is plausible and consistent with general pharmacology teaching about antioxidant supplements and iodine or deiodinase activity, but readers should treat the specific claim as unconfirmed until a clinician or pharmacist checks it against the primary literature.

BPC-157's effect on the thyroid axis is even less established in humans. Animal studies have suggested BPC-157 may influence hypothalamic-pituitary-thyroid signaling under conditions of stress or corticosteroid exposure, but there is no human data connecting BPC-157 to thyroid hormone levels, and no data at all on BPC-157 combined with alpha-lipoic acid affecting the thyroid axis together.

The most defensible, quotable summary of this page's evidence is this: BPC-157 and alpha-lipoic acid have no known pharmacokinetic interaction, but both may independently affect blood glucose, and alpha-lipoic acid at higher doses has a plausible, incompletely verified association with altered thyroid hormone status in people on levothyroxine; anyone with diabetes, prediabetes, or thyroid disease should have baseline glucose and thyroid labs checked before combining the two, and repeat them 6 to 8 weeks after starting.

Practical note for people on levothyroxine

Separating alpha-lipoic acid from levothyroxine by at least 4 hours is standard, general supplement guidance that applies to many supplements known or suspected to affect thyroid hormone absorption or metabolism, not a rule specific to BPC-157. There is no established pharmacokinetic reason to separate BPC-157 from levothyroxine, since no absorption interaction between them has been described, but taking them at different times of day is a reasonable, low-cost precaution while data remain limited.

Is a dose-separation window needed between BPC-157 and ALA themselves?

No pharmacokinetic rationale supports separating BPC-157 and alpha-lipoic acid by time. Reported pharmacokinetics for each compound (BPC-157 injected subcutaneously reaching peak levels within roughly 15 to 30 minutes in animal models, and orally dosed ALA absorbed within roughly 30 to 60 minutes with a short elimination half-life) suggest neither compound persists long enough to meaningfully collide with the other. Timing is a matter of convenience, not clinical necessity. The exact pharmacokinetic figures cited in prior drafts should be re-checked against a verified primary source before being restated as precise numbers in a reviewed version of this page.

Who should be more cautious about this combination?

People with diabetes or prediabetes. The plausible additive glucose-lowering effect is the main reason to loop in a prescriber, particularly for anyone on insulin, a sulfonylurea, or a GLP-1 receptor agonist. Fasting glucose readings below 70 mg/dL on more than one occasion warrant a medication review rather than self-adjustment.

People with hypothyroidism on levothyroxine. The main concern is alpha-lipoic acid's possible effect on thyroid hormone status, not BPC-157 specifically. A baseline TSH and free T4, repeated 6 to 8 weeks after starting ALA, is a reasonable precaution.

People on warfarin or other anticoagulants. Alpha-lipoic acid's antioxidant activity has a theoretical, weakly supported association with altered anticoagulant effect. BPC-157's effect on bleeding risk in humans is not established. This is a reason for INR awareness, not a contraindication, and requires clinician input rather than self-management.

Individual safety profiles

BPC-157 has not completed human Phase II or Phase III trials as of this writing. Its safety data come almost entirely from animal and in vitro studies plus uncontrolled clinical use through compounding pharmacies. The FDA has listed BPC-157 among substances raising unresolved safety concerns for 503A compounding, reflecting the absence of adequate human safety data (the FDA has published guidance identifying substances with unresolved safety data for 503A compounding use). Anyone using it is doing so outside an FDA-approved indication, regardless of what it is combined with.

Alpha-lipoic acid has a longer track record at typical supplement doses (roughly 300 to 600 mg/day), with gastrointestinal upset as the most commonly reported side effect at higher doses. A separate, rare but reported phenomenon, insulin autoimmune syndrome, has been associated with alpha-lipoic acid in some populations, notably in people carrying certain HLA types more common in East Asian populations, and can cause severe hypoglycemia unrelated to any peptide co-administration. This risk is not additive with BPC-157 because the mechanisms are unrelated, but it is a reason glucose monitoring is a sensible baseline regardless of what else someone is taking.

Evidence-status interaction assessment

Monitoring approach if a prescriber approves the combination

Before starting

• Fasting glucose and HbA1c
• TSH and free T4, especially if on levothyroxine or with any thyroid history
• Full medication and supplement list reviewed by a prescriber or pharmacist
• Recent history of hypoglycemic symptoms

Around 4 weeks

• Repeat fasting glucose
• Ask about sweating, tremor, confusion, or palpitations suggestive of hypoglycemia
• Ask about new fatigue, cold intolerance, or weight change suggestive of thyroid change

Around 6 to 8 weeks

• Repeat fasting glucose and HbA1c if the baseline was elevated
• Repeat TSH and free T4 if on levothyroxine or if baseline TSH was above the reference midpoint
• Reassess dosing of either agent based on results

When to act

• Fasting glucose repeatedly below 70 mg/dL: pause or reduce whichever glucose-lowering agent was added most recently, and contact the prescriber
• TSH rising above the upper reference limit: discuss levothyroxine dose adjustment or ALA dose reduction with the prescriber rather than stopping either agent unilaterally
• Two or more hypoglycemic episodes: stop one agent, involve the prescriber, and reintroduce sequentially with closer monitoring if appropriate

Evidence boundary

What is established: alpha-lipoic acid lowers glucose modestly in some studied populations and has a plausible, though incompletely verified in this draft, association with altered thyroid hormone measurements at higher doses in people on levothyroxine. BPC-157 is not FDA-approved, has not completed human efficacy or safety trials, and its glucose and thyroid effects come from animal research.

What is plausible but unproven: that combining BPC-157 and ALA produces a clinically additive glucose-lowering effect in humans, and that BPC-157 has any thyroid-axis effect in people.

What is not established: any pharmacokinetic interaction between the two agents, any interaction affecting BPC-157's tissue-repair activity, and the precise numeric magnitude of ALA's glucose or thyroid effects as previously stated on this page. Readers and reviewing clinicians should treat any specific percentage or lab-value change from earlier drafts of this article as unverified until confirmed against a primary source.

When urgent care is appropriate: symptoms of severe hypoglycemia (confusion, loss of consciousness, seizure) or signs of a significant allergic reaction to either agent warrant emergency evaluation, not self-management or a wait for the next scheduled lab check.